Optimer/Cubist's Dificid is Poised to Challenge Vancocin Usage in the Treatment of Clostridium Difficile Infection Patients with Severe Disease or Recurrent Infection According to Results from a New LaunchTrends Institutional Study.

Contents in vLex United States

• Contracts
• News and Business
• Case Law
• U.S. Code
• Legal Books and Journals
• Regulations
• Constitutions
• Tags
• Sources

Explore vLex

• Countries in vLex
• Publishers in vLex
• Testimonials

For Professionals

• Free trial
• Professional Subscription
• Corporate Subscriptions
• Librarian Center
• Search API

For Partners

• For Publishers
• For Authors

Company

• About us
• Press Room
• Work with us
• Terms of Use